A kit for determining for a female subject the implantation potential of embryos obtained or to be obtained by assisted fertilization is described. The kit includes at least one reagent suitable for detection of levels of FF G-CSF or FF G-CSF mRNA, such as anti-G-CSF antibody or a nucleic acid probe for detection of levels of G-CSF mRNA. The kit may also include a set of concentration standards of FF G-CSF and aspirator tips for removing an oocyte and follicular fluid.

The present invention relates to the diagnosis, monitoring, and/or treatment of medical conditions and/or a predisposition thereto. The condition preferably is dry eye disease. Described herein are methods, kits, and devices for diagnosing and monitoring dry eye disease in a subject.

The present disclosure teaches an assay to determine the likelihood of a successful implantation of an embryo into a female subject leading to a pregnancy. Enabled herein is an improved assisted reproduction technology protocol based on a prognostic evaluation of pregnancy outcomes. Taught herein is a composition comprising reagents required for the prognostic evaluation. Taught herein are assays comprising determination of levels of the biomarkers IL-8, G-CSF and/or VEGFA in a biological fluid sample taken before embryo implantation.

The present invention relates to the field of inflammatory bowel disease. More specifically, the present invention relates to the use of cytokines to detect, diagnose, and assess inflammatory bowel disease. In one embodiment, a method for diagnosing Crohn's Disease (CD) in a patient comprises the steps of (a) collecting a sample from the patient; (b) measuring the levels of at least one cytokine in the sample collected from the patient; and (c) comparing the levels of the at least one cytokine with predefined cytokine levels, wherein a correlation between the cytokine levels in the patient sample and predefined cytokine levels indicates that the patient has CD. In a specific embodiment, the at least one cytokine comprises Interferon (IFN)-gamma, Interleukin (IL)-1beta, IL-6, IL-8, IL-12, IL-17 and CXCL10.

Disclosed are novel biomarkers and methods related to diagnostic tests for the detection and characterization of inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis. In particular, the instant invention relates to novel biomarkers and methods of using such biomarkers to predict disease behavior and severity, to differentiate among disease types, and to optimize selection of treatment options in individuals suspected of having an inflammatory bowel disease.

Disclosed herein are anti-GM-CSF antibodies capable of binding to human GM-CSF and blocking its biological activities. Also provided herein are pharmaceutical compositions comprising the anti-GM-CSF antibodies and therapeutic and diagnostic uses of such antibodies.

The present disclosure is directed, in some aspects to methods and compositions for the assessment of regulatory T cell stability over time. In other aspects, the present disclosure provides methods and compositions for expanding regulatory T cells in culture.

The invention provides methods and systems for detecting a biomarker in a synovial fluid wherein the system also includes a control to ensure that the test sample is indeed synovial fluid. The biomarkers and the control for synovial fluid can be identified using proteomic methods, including but not limited to antibody based methods, such as an enzyme-linked immunosorbant assay (ELISA), a radioimmunoassay (RIA), or a lateral flow immunoassay.

The invention provides methods and systems for detecting a biomarker in a synovial fluid wherein the system also includes a control to ensure that the test sample is indeed synovial fluid. The biomarkers and the control for synovial fluid can be identified using proteomic methods, including but not limited to antibody based methods, such as an enzyme-linked immunosorbant assay (ELISA), a radioimmunoassay (RIA), or a lateral flow immunoassay.

The present invention relates to several biomarkers, including IL-1RA, IFN- and GM-CSF, whose expressions at the mRNA level and at the protein level, correlate with chronic pathologies, such as Lyme disease, in particular the late chronic form of Lyme disease. More specifically, the invention provides methods and kits for the diagnosis of such chronic pathologies and for the assessment of a patient's response to a treatment, as well as methods and therapeutic agents for the treatment of such chronic pathologies.